IRWD Q4 2022 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$629M

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$107M-8.5% YoY

Gross Profit

$107M99.7% margin

Operating Income

$68M63.8% margin

Net Income

$49M45.6% margin

EPS (Diluted)

$0.26

QoQ Revenue Growth

-1.3%

Cash Flow

Operating Cash Flow

$79M

Free Cash Flow

$79M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$448M

Stockholders' Equity

$652M

Cash & Equivalents

$656M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$107M	$117M	-8.5%
Gross Profit	$107M	$117M	-8.5%
Operating Income	$68M	$57M	+20.8%
Net Income	$49M	$41M	+18.1%

Revenue Segments

Collaborative arrangements revenue

$107M99%

Collaborative arrangement, other agreements

$570,0001%

Collaborative arrangement, collaboration and license agreements

$151,0000%

Geographic Segments

North America

$679,00036%

Canada and Mexico

$600,00032%

Europe and Other

$597,00032%